Drug
low dose cytarabine
low dose cytarabine is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_1
1
25%
Ph phase_2
2
50%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Other(1)
Detailed Status
Completed2
Active, not recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)
Trials by Status
active_not_recruiting125%
completed250%
unknown125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_1
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
NCT04891757
completedphase_2
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
NCT02084563
unknownnot_applicable
Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old
NCT02432911
completedphase_2
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
NCT00528333
Clinical Trials (4)
Showing 4 of 4 trials
NCT04891757Phase 1
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
NCT02084563Phase 2
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
NCT02432911Not Applicable
Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old
NCT00528333Phase 2
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4